Pharmaceutical Report

When looking at the Digital Strength Index, pharmaceutical companies score on the low end of the spectrum overall. Even though Big Pharma could be considered digitally nascent, they just have a different interpretation of what digital transformation means. By making digital a priority, the system will become not only more efficient but more effective, allowing Big Pharma to focus on selling outcomes, not pills.

Key Findings

  • AbbVie is the high-growth ticker, aided by its relatively higher digital share among pharmaceuticals and recent Momentum.
  • Merck’s digital strength assessment points to continued headwinds for future topline revenue growth.
  • Johnson & Johnson has the largest digital presence by far in terms of digital properties and overall consumer interactions across platforms.
  • Pfizer’s digital strength has started to lose some Momentum but the company has a leg up on the peer group in driving interactions in Search and Social.


Weighted Scorecard

Johnson & Johnson and Pfizer lead in Magnitude due to their consumer-facing brands. However, the companies with consumer health divisions are starting to lose momentum, while smaller companies like AbbVie are catching up.

Embracing Innovation

Big Pharma has been characteristically conservative in its adoption of new digital technologies. How can the Pharma industry make a change and leverage digital innovation to avoid losing ground?

Download our report to find out. 




More News

| 16th Apr 2021

Get the Squeeze on Claire Bartosic

Our people are what make us special, get The Squeeze on the Isobar team.

| 15th Apr 2021

To DTC or Not to DTC? How Direct-to-Consumer Is Evolving

DTC has exploded amid the rise of the stay-at-home economy, and providing a lovable customer experience will separate the leaders from the followers.

| 9th Apr 2021

Forrester Names Dentsu a Strong Performer

Dentsu is proud to be named a Strong Performer in The Forrester Wave: Commerce Services, Q1 2021.